

**Table 1: Characteristics of patients tested for germline *BRCA1* and *BRCA2* mutations**

Characteristics	Total (n=431)		BRCA mutations	
	Number	(%)	Number	(%)
<b>Female breast, age at index diagnosis, y</b>				
≤30	50	11.6	10	20.0
31-40	164	38.1	30	18.3
41-50	144	33.4	16	11.1
>50	73	16.9	9	12.3
<b>Breast or ovarian cancers in family (1° and 2° only)</b>				
Female breast	217	50.3	41	18.9
Female ovary	19	4.4	9	47.4
<b>Manchester score</b>				
≤10	205	47.6	11	5.4
11-17	146	33.9	26	17.8
≥18	80	18.6	28	35.0
<b>Ancestry</b>				
Malay	115	26.7	17	14.8
Chinese	248	57.5	31	12.5
Indian	59	13.7	15	25.4
Others	9	2.1	2	22.2
<b>Referral characteristic</b>				
Early onset ≤35, regardless of family history	131	30.4	25	19.1
2 cases of breast cancer, 1 <50	126	29.2	21	16.7
3 cases of breast or ovarian cancer	76	17.6	25	32.9
1 case of bilateral breast cancer <50, in index or 1° and 2° relative	39	9.0	13	33.3
1 case of breast and ovarian cancer in same individual in index or 1° and 2° relative	8	1.9	4	50.0
Triple negative breast cancer, ≤50	98	22.7	23	23.5

A total of 431 breast cancer patients were analysed for germline mutations in *BRCA1* and *BRCA2* by DNA sequencing and multiple ligation dependent probe amplification (MLPA) analysis. Table 1 shows the distribution of patients according to their age at diagnosis, family history of breast and ovarian cancer in first- and second degree relatives, Manchester score and self-declared ethnicity, and the prevalence of *BRCA1* and *BRCA2* mutations in each category.

